Met-HeFT meta-analysisHot Line 6Heart Failure
Metformin in Heart Failure and Ischaemic Heart Disease
Metformin in heart failure and ischaemic heart disease: a meta-analysis
Presenting authorAnders Hostrup LarsenHeart Failure / Cardiomyopathy · Aarhus UniversityAnders Hostrup Larsen, MD, PhD, is a cardiologist and associate professor at the Department of Cardiology, Gødstrup Hospital in Herning, Denmark, with an academic affiliation at Aarhus University. He completed his PhD at Aarhus University in 2020 on metformin treatment in heart failure patients, including myocardial energetics and cardiac uptake of metformin. He has been involved in clinical research since 2015, with work on heart failure metabolism, insulin resistance, PET imaging, and stress echocardiography.
Overview
Metformin effects in HF with IHD remain uncertain; pending ESC 2026 meta-analysis will extend evidence synthesis for practice and trials.
Key result
Metformin outcomes in patients with heart failure and ischaemic heart disease are currently pending presentation from a late-breaking meta-analysis.
Discussion
Expert reaction lands here the moment Met-HeFT meta-analysis reports.
Key Points
- Evaluation of metformin therapy aims to assess cardiovascular outcomes in patients diagnosed with heart failure and ischaemic heart disease.
- Evidence synthesis targets major clinical endpoints across trial datasets, though quantitative efficacy metrics remain pending formal release.
- Meta-analysis synthesizes cardiovascular study data for late-breaking presentation at the European Society of Cardiology Congress 2026 session.
Main Result
Absolute Event Rate: 0% vs 0%